Can initial tacrolimus trough levels be predicted from clinical variables?

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Cardiac transplantation is a definitive treatment for end-stage heart failure.
• Calcineurin inhibitors like tacrolimus are essential for preventing rejection but can cause renal toxicity.
• Limiting tacrolimus levels may reduce renal insufficiency.

Purpose of the Study:

• To identify clinical or laboratory variables predicting rapid changes in tacrolimus target levels after cardiac transplantation.
• To develop a predictive model for elevated tacrolimus trough levels.

Main Methods:

• A standard 1-mg oral test dose of tacrolimus was administered.
• Various clinical and laboratory variables were assessed, including liver metabolism indices (alanine aminotransferase, total bilirubin), serum creatinine, demographics, and right ventricular function.
• Patients with tacrolimus trough levels >= 4.5 ng/dL were considered to have elevated levels.

Main Results:

• No single variable strongly predicted high tacrolimus trough levels.
• A combination of alanine aminotransferase, total bilirubin, and serum creatinine effectively identified patients tending toward elevated tacrolimus levels.
• Demographics and echocardiographic right ventricular function did not improve the predictive accuracy.

Conclusions:

• A simple scoring system incorporating liver function tests and serum creatinine can identify cardiac transplant patients at risk of elevated tacrolimus levels.
• This predictive model may aid in proactive management to mitigate renal toxicity associated with calcineurin inhibitors.